subscribeSubscribe
BerGenBio Announces Data Indicating Broadened Potential for Bemcentinib

BerGenBio Announces Data Indicating Broadened Potential for Bemcentinib
PR NEWSWIRE
07 Feb 2024
Share Share
Data on BerGenBio`s selective AXL inhibitor bemcentinib to be presented

Data on BerGenBio`s selective AXL inhibitor bemcentinib to be presented
PR NEWSWIRE
16 Oct 2023
Share Share
BerGenBio announces data presentations showing activity of bemcentinib in NSCLC

BerGenBio announces data presentations showing activity of bemcentinib in NSCLC
PR NEWSWIRE
22 Aug 2023
Share Share
BerGenBio Announces First Patient Dosed in Ph1b/2a Trial Evaluating Bemcentinib

BerGenBio Announces First Patient Dosed in Ph1b/2a Trial Evaluating Bemcentinib
PR NEWSWIRE
09 Mar 2023
Share Share
BerGenBio randomises first patient in Covid-19 treatment study

BerGenBio randomises first patient in Covid-19 treatment study
CLINICALTRIALSARENA
28 Sep 2022
Share Share
BerGenBio, Oslo University`s Bemcentinib will be Studied in EU-SolidAct trial

BerGenBio, Oslo University`s Bemcentinib will be Studied in EU-SolidAct trial
PRNEWSWIRE
27 Jan 2022
Share Share
BerGenBio Receives FDA Fast Track Designation For Bemcentinib In STK11 (NSCLC)

BerGenBio Receives FDA Fast Track Designation For Bemcentinib In STK11 (NSCLC)
PRNEWSWIRE
09 Nov 2021
Share Share
BerGenBio Receives Fast Track Designation For Bemcentinib / Anti-PD-(L)1

BerGenBio Receives Fast Track Designation For Bemcentinib / Anti-PD-(L)1
PRNEWSWIRE
08 Jun 2021
Share Share
BerGenBio to Present Top Line Translational Phase II Data With Bemcentinib

BerGenBio to Present Top Line Translational Phase II Data With Bemcentinib
PRNEWSWIRE
14 Jun 2020
Share Share
First patient dosed in bemcentinib COVID-19 trial

First patient dosed in bemcentinib COVID-19 trial
Selina McKee PHARMA TIMES
02 Jun 2020
Share Share